Placental Growth Factor Negatively Regulates Retinal Endothelial Cell Barrier Function Through Suppression of Glucose-6-phosphate Dehydrogenase and Antioxidant Defense Systems

Overview

Journal FASEB J

Specialties Biology
Physiology

Date 2019 Oct 6

PMID 31585507

Citations 16

Authors

Hu Huang

Anton Lennikov

Madhu Sudhana Saddala

David Gozal

Dennis J Grab

Abdelnaby Khalyfa

Lijuan Fan

Affiliations

Soon will be listed here.

Abstract

We report that placental growth factor (PlGF) negatively affects the endothelial cell (EC) barrier function through a novel regulatory mechanism. The PlGF mAb promotes (but recombinant protein disrupts) EC barrier function, thus affecting the barrier-forming protein levels, membrane distribution, and EC monolayer impedance by the electrical cell-impedance sensing system, Western blot, and immunofluorescence staining. RNA sequencing-based transcriptome analysis identified the up-regulation of the pentose phosphate pathway (PPP) and the antioxidant defense protein by PlGF blockade. The PlGF and PlGF/VEGF dimers (but not VEGF-A) down-regulated the protein expression of glucose-6-phosphate dehydrogenase (G6PD) and peroxiredoxin (PRDX). G6PD inhibition and gene silencing (small interfering RNA) abolished the beneficial effects of PlGF inhibition on EC barrier function and PRDX3/6 protein expression. VEGF receptor (VEGFR)1 or VEGFR2 blockade prevented the inhibitory effect of PlGF on G6PD protein expression and EC barrier function. The PRDX6 played dual roles in EC barrier function through glutathione peroxidase and phospholipase A activity. In sum, PlGF negatively regulates EC barrier function through the activation of VEGFR1 and VEGFR2 and the suppression of the G6PD/PPP and the antioxidant pathways.-Huang, H., Lennikov, A., Saddala, M. S., Gozal, D., Grab, D. J., Khalyfa, A., Fan, L. Placental growth factor negatively regulates endothelial cell barrier function through suppression of glucose-6-phosphate dehydrogenase and antioxidant defense systems.

Citing Articles

Aflibercept Off-Target Effects in Diabetic Macular Edema: An In Silico Modeling Approach.

Blanot M, Casaroli-Marano R, Mondejar-Medrano J, Sallen T, Ramirez E, Segu-Verges C Int J Mol Sci. 2024; 25(7).

PMID: 38612432 PMC: 11011561. DOI: 10.3390/ijms25073621.

IGFBPL1 is a master driver of microglia homeostasis and resolution of neuroinflammation in glaucoma and brain tauopathy.

Pan L, Cho K, Wei X, Xu F, Lennikov A, Hu G Cell Rep. 2023; 42(8):112889.

PMID: 37527036 PMC: 10528709. DOI: 10.1016/j.celrep.2023.112889.

Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases.

Sharma D, Zachary I, Jia H Invest Ophthalmol Vis Sci. 2023; 64(5):28.

PMID: 37252731 PMC: 10230445. DOI: 10.1167/iovs.64.5.28.

Pentose Pathway Activation Is Superior to Increased Glycolysis for Therapeutic Angiogenesis in Peripheral Arterial Disease.

Zaied A, Ushio-Fukai M, Fukai T, Kovacs-Kasa A, Alhusban S, Sudhahar V J Am Heart Assoc. 2023; 12(7):e027986.

PMID: 36974760 PMC: 10122893. DOI: 10.1161/JAHA.122.027986.

Association of Placental Growth Factor and Angiopoietin in Human Retinal Endothelial Cell-Pericyte co-Cultures and iPSC-Derived Vascular Organoids.

Huang H, Saddala M, Mukwaya A, Mohan R, Lennikov A Curr Eye Res. 2022; 48(3):297-311.

PMID: 36458540 PMC: 10417885. DOI: 10.1080/02713683.2022.2149808.

References

Hagberg C, Mehlem A, Falkevall A, Muhl L, Fam B, Ortsater H . Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes. Nature. 2012; 490(7420):426-30. DOI: 10.1038/nature11464. View

Snuderl M, Batista A, Kirkpatrick N, Ruiz de Almodovar C, Riedemann L, Walsh E . Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell. 2013; 152(5):1065-76. PMC: 3587980. DOI: 10.1016/j.cell.2013.01.036. View

Kowalczuk L, Touchard E, Omri S, Jonet L, Klein C, Valamanes F . Placental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy. PLoS One. 2011; 6(3):e17462. PMC: 3049767. DOI: 10.1371/journal.pone.0017462. View

Huang H, Shen J, Vinores S . Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye. PLoS One. 2011; 6(6):e21411. PMC: 3120882. DOI: 10.1371/journal.pone.0021411. View

Giaever I, Keese C . Micromotion of mammalian cells measured electrically. Proc Natl Acad Sci U S A. 1991; 88(17):7896-900. PMC: 52411. DOI: 10.1073/pnas.88.17.7896. View

Cosentino C, Grieco D, Costanzo V . ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J. 2010; 30(3):546-55. PMC: 3034007. DOI: 10.1038/emboj.2010.330. View

Antonetti D, Klein R, Gardner T . Diabetic retinopathy. N Engl J Med. 2012; 366(13):1227-39. DOI: 10.1056/NEJMra1005073. View

Jiang P, Du W, Wu M . Regulation of the pentose phosphate pathway in cancer. Protein Cell. 2014; 5(8):592-602. PMC: 4112277. DOI: 10.1007/s13238-014-0082-8. View

Fisher A . The phospholipase A activity of peroxiredoxin 6. J Lipid Res. 2018; 59(7):1132-1147. PMC: 6027911. DOI: 10.1194/jlr.R082578. View

10.

Nguyen Q, De Falco S, Behar-Cohen F, Lam W, Li X, Reichhart N . Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmol. 2016; 96(1):e1-e9. PMC: 5811779. DOI: 10.1111/aos.13325. View

11.

Al Kahtani E, Xu Z, Al Rashaed S, Wu L, Mahale A, Tian J . Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment. Eye (Lond). 2016; 31(4):529-536. PMC: 5395987. DOI: 10.1038/eye.2016.246. View

12.

Wells J, Glassman A, Ayala A, Jampol L, Aiello L, Antoszyk A . Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015; 372(13):1193-203. PMC: 4422053. DOI: 10.1056/NEJMoa1414264. View

13.

Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F . Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002; 8(8):831-40. DOI: 10.1038/nm731. View

14.

Huang H, Van de Veire S, Dalal M, Parlier R, Semba R, Carmeliet P . Reduced retinal neovascularization, vascular permeability, and apoptosis in ischemic retinopathy in the absence of prolyl hydroxylase-1 due to the prevention of hyperoxia-induced vascular obliteration. Invest Ophthalmol Vis Sci. 2011; 52(10):7565-73. PMC: 3183980. DOI: 10.1167/iovs.11-8002. View

15.

Cai J, Wu L, Qi X, Shaw L, Li Calzi S, Caballero S . Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability. PLoS One. 2011; 6(3):e18076. PMC: 3064593. DOI: 10.1371/journal.pone.0018076. View

16.

Saddala M, Lennikov A, Grab D, Liu G, Tang S, Huang H . Proteomics reveals ablation of PlGF increases antioxidant and neuroprotective proteins in the diabetic mouse retina. Sci Rep. 2018; 8(1):16728. PMC: 6233167. DOI: 10.1038/s41598-018-34955-x. View

17.

Quaegebeur A, Segura I, Schmieder R, Verdegem D, Decimo I, Bifari F . Deletion or Inhibition of the Oxygen Sensor PHD1 Protects against Ischemic Stroke via Reprogramming of Neuronal Metabolism. Cell Metab. 2016; 23(2):280-91. PMC: 4880550. DOI: 10.1016/j.cmet.2015.12.007. View

18.

Zhao Z, Nelson A, Betsholtz C, Zlokovic B . Establishment and Dysfunction of the Blood-Brain Barrier. Cell. 2015; 163(5):1064-1078. PMC: 4655822. DOI: 10.1016/j.cell.2015.10.067. View

19.

Bolger A, Lohse M, Usadel B . Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014; 30(15):2114-20. PMC: 4103590. DOI: 10.1093/bioinformatics/btu170. View

20.

Miyamoto N, De Kozak Y, Jeanny J, Glotin A, Mascarelli F, Massin P . Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy. Diabetologia. 2006; 50(2):461-70. DOI: 10.1007/s00125-006-0539-2. View